We have previously shown that Hispanic ethnicity influences progression to T1D with interaction by obesity in children < 12 years of age. In this study, we aimed to compare ethnicities for characteristics in the peri-diagnostic period of T1D. We studied participants in TrialNet New Onset Intervention Trials (n=501, 9.4% Hispanics, 86.4% non-Hispanic whites [NHW], 4.2% non-Hispanic other) followed prospectively. We analyzed clinical, immunological and metabolic characteristics in the peri-diagnostic period of T1D. Mixed meal tolerance tests (MMTT) were performed within 6 months (median: 2 months, range: 4 days - 6 months) following diagnosis and then every 5-6 months in the first 3 years after diagnosis. Race and ethnicity categories were based on self-report and on standard NIH classifications. Unless otherwise indicated, all analyses were adjusted for age, age and sex-adjusted BMI Z-score, sex, as well as days from diagnosis to MMTT. Median ages (IQR) at enrollment were 14.1(6) years in Hispanics and 14.3(7.5) years in NHW. 44.7% of Hispanics and 41.8% of NHW were female. At T1D clinical diagnosis, Hispanics, compared with NHW, had a higher frequency of diabetic ketoacidosis [DKA] (42.9% vs. 22.8%, OR=2.45, p=0.008), lower fasting glucose (97.5 vs. 108.5 mg/dL, p=0.011), higher frequency of ZnT8 autoantibody positivity (n=201, 94.1% vs. 63.5%, p=0.039), and a trend for higher fasting C-peptide (0.39 vs. 0.32 ng/mL, p=0.093). When analyzing C-peptide trajectories by ethnicity in eligible participants (n=310), there were no significant differences during 3-year follow-up after adjusting for BMI-Z score and age (mean C-peptide AUC, p=0.74).

In conclusion, despite ethnic differences in the frequency of DKA, and metabolic and immunological characteristics at clinical diagnosis of T1D, C-peptide trajectories did not differ in the first 3 years following diagnosis between Hispanics and NHW. These findings may inform the design of observational studies and intervention trials in the peri-diagnostic period of T1D.


M. Tosur: None. M.A. Cleves: None. J. Sosenko: None. I. Libman: Consultant; Self; Novo Nordisk Inc. D. Baidal: None. M.J. Redondo: None.


National Institute of Diabetes and Digestive and Kidney Diseases

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.